ICU Medical (ICUI) Could Be 2% Undervalued As Recall Questions Meet A Full P E
ICU Medical (ICUI) is in focus after US regulators published enforcement reports on voluntary Class II recalls of its Plum Duo and Plum Solo infusion pumps, citing a software issue affecting displayed dosing volumes.
See our latest analysis for ICU Medical.
The US Food and Drug Administration recall news lands against a backdrop of strong recent momentum in ICU Medical's share price, with a 30 day share price return of 13.51% and a 1 year total shareholder return of 32.27%, even as the 5 year total shareholder return is down 12.82%.
If this kind of product focused story has your attention, it could be a good moment to broaden your search using our healthcare focused screener for 41 healthcare AI stocks
ICU Medical has rallied hard in recent months even as the pump recalls stay in the headlines. Does it make more sense to accept today’s price, or to wait for a cleaner entry point once the valuation work is clear?
Most Popular Narrative: 2.3% Undervalued
ICU Medical's most followed narrative points to a fair value of $172.50, which sits only slightly above the latest close at $168.51. That small gap keeps the focus squarely on the quality of the assumptions behind the story rather than a big valuation disconnect.
The multiyear replacement cycle for ICU Medical's large installed base of infusion pumps is only now beginning, with refresh and value-capture opportunities expected to meaningfully contribute to revenue growth and recurring cash flows starting next year. Positive forward looking catalyst for both top line and earnings.
Want to see what sits behind that pump replacement theme? The narrative leans on measured revenue growth, rising margins, and a future earnings multiple that needs real follow through. Curious how those moving parts combine to support the fair value.
Result: Fair Value of $172.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ICU Medical's story can quickly shift if regulatory scrutiny around recalls escalates, or if tariff and integration costs weigh more heavily on margins than expected.
Find out about the key risks to this ICU Medical narrative.
Another View: ICU Medical Through The Earnings Lens
The first story around ICU Medical leans on a fair value of $172.50 and a modest 2.3% discount to the current share price. Yet on a simple earnings lens, the stock trades on a P/E of 90.9x, well above the US Medical Equipment industry on 28.8x and peers on 31.7x.
The fair ratio sits at 32.8x, so the current multiple is almost three times the level the market could move towards. That gap points to meaningful valuation risk if sentiment cools or if future results fall short of expectations. Which valuation story do you place more weight on?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With ICU Medical drawing strong reactions on both risks and potential rewards, it may be useful to move quickly and review the numbers yourself. To get a balanced view before sentiment shifts again, check the 3 key rewards and 3 important warning signs
Looking for more ICU Medical style investment ideas?
If ICU Medical has sharpened your focus, do not stop here. Use targeted stock lists to spot opportunities that match your goals before the crowd catches on.
- Target long term compounding potential with our list of companies trading below estimated value through the 55 high quality undervalued stocks
- Prioritise resilience by scanning for companies with low risk scores using the 81 resilient stocks with low risk scores
- Hunt for promising under followed opportunities by checking the screener containing 19 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com